Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
![mainstay-300x300](https://ipfpartners.com/wp-content/uploads/2019/05/mainstay-300x300.jpg)
Mainstay Medical Holdings plc today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Premarket Approval (PMA) application for ReActiv8®, its implantable neurostimulation system to treat intractable chronic low back pain.